Evaluation of analgesic activity of irbesartan in albino mice

P. S. Vaibhavi, R. N. Suresha, H. L. Kalabharathi, Siddamma Amogimath, M. K. Jayanthi, K. Padmaja Shetty

Abstract


Background: The objective was to evaluate the analgesic activity of irbesartan in albino mice.

Methods: Swiss albino mice weighing 25-30 g of either sex were selected for the study. Six animals were allocated to each experimental group. The control group received normal saline (25 ml/kg, p.o.), standard group received pentazocine (10mg/kg, intraperitonial [i.p.]) and test group received irbesartan (20 mg/kg, p.o.). The above drugs were administered 1 hr prior to the experiments. In case of visceral pain model 0.6% acetic acid was given i.p. 30 mins prior to the experiment to induce writhing, in thermal pain model pretreated mice were placed on Eddy’s Hotplate maintained at 55°C and in mechanical stimulus pain model an artery clip was clamped at the base of the tail of pretreated mice. Decrease in total number of writhes in acetic acid induced writhing model and delay in reaction time in both Eddy’s hot plate and Tail clip method denoted analgesic activity respectively.

Results: The test drug significantly decreased the total number of writhes in acetic acid induced writhing model in mice. The percentage inhibition of writhing was significant which was 84.35% in the standard group and 59.24% in the test group. The test drug significantly delayed the reaction time in both Eddy’s hot plate and tail clip method when compared to control group and standard group. Percentage increase in latency period when compared to standard drug was significant and measured 73.11% and 64.31% at 60 min in both Eddy’s hot plate and tail clip method, respectively.

Conclusion: Irbesartan exhibits analgesic activity in albino mice.


Keywords


Angiotensin II, Irbesartan, Analgesia, Proinflammatory molecule

Full Text:

PDF

References


Grosser T, Smyth E, FitzGerald GA. Anti-inflammatory, antipyretic and analgesic agents; Pharmacotherapy of gout. In: Brunton LL, Chabner BA, Knollman BC, editors. Goodman and Gillman's the Pharmacological Basis of Therapeutics. 12th Edition. China: McGraw Hill; 2011: 959-64.

Robbins SL, Cotran RS. Acute and chronic inflammation. In: Kumar V, Abbas AK, Fausto N, editors. Robbins and Cotran Pathological Basis of Diseases. 7th Edition. Noida: Elseiver; 2008: 48-55.

Li-Qin Z, Jie-Li H, Yu Y, Lu Y, Fu LJ, Wang JL, et al. Candesartan inhibits LPS-induced expression increase of toll-like receptor 4 and downstream inflammatory factors likely via angiotensin II type 1 receptor independent pathway in human renal tubular epithelial cells. Acta Physiol Sinica. 2013;65(6):623-30.

Ruiz-Ortega M, Bustos C, Hernández-Presa MA, Lorenzo O, Plaza JJ, Egido J, et al. Angiotensin-II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa I activation and monocyte chemoattractant protein-1 synthesis. J Immunol. 1998;161:430-9.

Dandona P, Kumar V, Aljada A, Ghanim H. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-κB, in mononuclear cells of normal subjects: evidence of an anti-inflammatory action. J Clin Endocrinol Metab. 2003;88:4496-501. [DOI via Crossref]

Koster R, Anderson M, De-Beer EJ. Acetic acid for analgesic screening. Fed Proc. 1959;18:412-8.

Shravan Kumar G, Rajesh K, Sengottuvelu S. Evaluation of analgesic and anti inflammatory activity of methanolic extract of cocculus hirsutos leaves. Int Res J Pharm. 2011;2(12):230-4.

Bianchi C, Francbschini J. Experimental observations on Haffner's method for testing analgesic drugs. Br J Pharmacol Chemother. 1954;9:280-4. [PubMed: 13199245] [DOI via Crossref]

Shivanand Reddy KV, Balaji J, Patil U. Antinociceptive activity of selective serotonin reuptake inhibitors in albino rats. Int Med J Stud Res. 2011;1(1):36-41.

Benowitz NC. Antihypertensive agents. In: Katzung BG, Masler SB, Thenor AJ, editors. Basic and Clinical Pharmacology. 11th Edition. New Delhi: Tata McGraw Hill; 2009: 181-3.

Tham DM, Martin-McNulty B, Wang YX, Wilson DW, Vergona R, Sullivan ME, et al. Angiotensin II is associated with activation of NF- κB-mediated genes and downregulation of PPARs. Physiol Genomics. 2002;11:21-30.

Funakoshi Y, Ichiki T, Ito K, Takeshita A. Cells induction of interleukin-6 expression by angiotensin II in rat vascular smooth muscle. Hypertens J Am Heart Assoc. 1999;34(1):118-25.

Das UN. Angiotensin-II behaves as an endogenous pro-inflammatory molecule. J Assoc Phys India. 2005;53:472-6.

Barros de Oliveira CM, Sakata RK. Cytokines and pain. Rev Bras Anestesiol. 2011;61:255-9. [DOI via Crossref]

Raiden S, Giordano M, Andonegui G, Trevani AS, López DH, Nahmod V, et al. Losartan, a selective inhibitor of subtype AT1 receptors for angiotensin II, inhibits the binding of N-Formylmethionylleucyl- phenylalanine to neutrophil receptors. J Pharmacol Exp Ther. 1997;281:624-8.

Omar ME, Salam A. Effect of ramipril, valsartan and candesartan on thermal and visceral pain in mice. J Pharmacol Toxicol. 2007;2(6):533-41. [DOI via Crossref]

Derardt R, Jongney S, Delevalcee F, Flahaut M. Release of prostaglandin E and F in an analgesic reaction and its inhibition. Eur J Pharmacol. 1980;51:17-24. [DOI via Crossref]

Paschapur MS. Evaluation of the analgesic and antipyretic activities of ethanolic extract of male flowers (inflorescences) of borassus flabellifer l. (arecaceae). Int J Pharm Pharm Sci. 2009;1(2):98-106.